605 related articles for article (PubMed ID: 20141543)
1. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
[TBL] [Abstract][Full Text] [Related]
2. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.
Hashiguchi M; Kobori H; Ritprajak P; Kamimura Y; Kozono H; Azuma M
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10495-500. PubMed ID: 18650384
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction.
Leitner J; Klauser C; Pickl WF; Stöckl J; Majdic O; Bardet AF; Kreil DP; Dong C; Yamazaki T; Zlabinger G; Pfistershammer K; Steinberger P
Eur J Immunol; 2009 Jul; 39(7):1754-64. PubMed ID: 19544488
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells.
Luo L; Chapoval AI; Flies DB; Zhu G; Hirano F; Wang S; Lau JS; Dong H; Tamada K; Flies AS; Liu Y; Chen L
J Immunol; 2004 Nov; 173(9):5445-50. PubMed ID: 15494491
[TBL] [Abstract][Full Text] [Related]
5. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
6. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
7. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.
Azuma M; Cayabyab M; Buck D; Phillips JH; Lanier LL
J Exp Med; 1992 Feb; 175(2):353-60. PubMed ID: 1370679
[TBL] [Abstract][Full Text] [Related]
8. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+) memory and effector cytotoxic T-lymphocyte responses.
Wang Y; Da'Dara AA; Thomas PG; Harn DA
Immunology; 2010 Mar; 129(3):406-17. PubMed ID: 19922421
[TBL] [Abstract][Full Text] [Related]
11. Clinical importance of B7-H3 expression in human pancreatic cancer.
Yamato I; Sho M; Nomi T; Akahori T; Shimada K; Hotta K; Kanehiro H; Konishi N; Yagita H; Nakajima Y
Br J Cancer; 2009 Nov; 101(10):1709-16. PubMed ID: 19844235
[TBL] [Abstract][Full Text] [Related]
12. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
13. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice.
Wang YC; Zhu L; McHugh R; Sell KW; Selvaraj P
Eur J Immunol; 1995 May; 25(5):1163-7. PubMed ID: 7774619
[TBL] [Abstract][Full Text] [Related]
14. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.
Keir ME; Freeman GJ; Sharpe AH
J Immunol; 2007 Oct; 179(8):5064-70. PubMed ID: 17911591
[TBL] [Abstract][Full Text] [Related]
15. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells.
Ramarathinam L; Castle M; Wu Y; Liu Y
J Exp Med; 1994 Apr; 179(4):1205-14. PubMed ID: 7511683
[TBL] [Abstract][Full Text] [Related]
16. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.
Pato A; Eisenberg G; Machlenkin A; Margalit A; Cafri G; Frankenburg S; Merims S; Peretz T; Lotem M; Gross G
Clin Exp Immunol; 2015 Nov; 182(2):220-9. PubMed ID: 26212048
[TBL] [Abstract][Full Text] [Related]
17. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
18. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Hamada H; Azuma M; Asano S
Int J Cancer; 1997 Nov; 73(4):556-61. PubMed ID: 9389572
[TBL] [Abstract][Full Text] [Related]
20. Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection.
Seo SK; Jeong HY; Park SG; Lee SW; Choi IW; Chen L; Choi I
Immunology; 2008 Jan; 123(1):90-9. PubMed ID: 17971153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
